Cargando…

Standardised incidence ratios (SIRs) for cancer after renal transplant in systemic lupus erythematosus (SLE) and non-SLE recipients

OBJECTIVE: We investigated malignancy risk after renal transplantation in patients with and without systemic lupus erythematosus (SLE). METHODS: Using the United States Renal Data System from 2001 to 2009, 143 652 renal transplant recipients with and without SLE contributed 585 420 patient-years of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ramsey-Goldman, Rosalind, Brar, Amarpali, Richardson, Carrie, Salifu, Moro O, Clarke, Ann, Bernatsky, Sasha, Stefanov, Dimitre G, Jindal, Rahul M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2016
Materias:	Lupus Nephritis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4908873/ https://www.ncbi.nlm.nih.gov/pubmed/27335659 http://dx.doi.org/10.1136/lupus-2016-000156

Ejemplares similares

p16(Ink4a), a marker of cellular senescence, is associated with renal disease in the B6.NZMSle1/Sle2/Sle3 mouse model of lupus
por: Tilman, Gaëlle, et al.
Publicado: (2023)

Mer-tyrosine kinase: a novel susceptibility gene for SLE related end-stage renal disease
por: Yavuz, Sule, et al.
Publicado: (2022)

Influence of renal complications on the efficacy and adverse events of tacrolimus combination therapy in patients with systemic lupus erythematosus (SLE) during a maintenance phase: a single-centre, prospective study
por: Ishii, Sho, et al.
Publicado: (2015)

Safety, pharmacokinetics and pharmacodynamics of AMG 811, an anti-interferon-γ monoclonal antibody, in SLE subjects without or with lupus nephritis
por: Boedigheimer, Michael J, et al.
Publicado: (2017)

Time to onset of clinical response to anifrolumab in patients with SLE: pooled data from the phase III TULIP-1 and TULIP-2 trials
por: Bruce, Ian N, et al.
Publicado: (2023)

Microvascular C5b-9 deposition in non-lesional skin in patients with SLE and its correlation with active lupus nephritis: a prospective observational study
por: Anderson, Meghan, et al.
Publicado: (2023)

Safety of procuring research tissue during a clinically indicated kidney biopsy from patients with lupus: data from the Accelerating Medicines Partnership RA/SLE Network
por: Deonaraine, Kristina K, et al.
Publicado: (2021)

Performance of the proposed ACR–EULAR classification criteria for systemic lupus erythematosus (SLE) in a cohort of patients with SLE with neuropsychiatric symptoms
por: Gegenava, Maka, et al.
Publicado: (2019)

Performance of the 2019 EULAR/ACR systemic lupus erythematosus classification criteria in a cohort of patients with biopsy-confirmed lupus nephritis
por: Wang, Huijing, et al.
Publicado: (2021)

Multicentre retrospective cohort study assessing the incidence of serious infections in patients with lupus nephritis, compared with non-renal systemic lupus erythematosus
por: Yates, Drew Joseph, et al.
Publicado: (2020)

One-third of patients with lupus nephritis classified as complete responders continue to accrue progressive renal damage despite resolution of proteinuria
por: Weeding, Emma, et al.
Publicado: (2022)

Lupus-related single nucleotide polymorphisms and risk of diffuse large B-cell lymphoma
por: Bernatsky, Sasha, et al.
Publicado: (2017)

Renal response at 2 years post biopsy to predict long-term renal survival in lupus nephritis: a retrospective analysis of the Hopkins Lupus Cohort
por: Cooper Blenkinsopp, Selin, et al.
Publicado: (2022)

What to Expect When Expecting With Systemic Lupus Erythematosus (SLE): A Population‐Based Study of Maternal and Fetal Outcomes in SLE and Pre‐SLE
por: Arkema, Elizabeth V., et al.
Publicado: (2016)

Role of early repeated renal biopsies in lupus nephritis
por: Zickert, A, et al.
Publicado: (2014)

Identification of clinical and serological factors during induction treatment of lupus nephritis that are associated with renal outcome
por: Dall'Era, Maria, et al.
Publicado: (2015)

Characterising the immune profile of the kidney biopsy at lupus nephritis flare differentiates early treatment responders from non-responders
por: Parikh, Samir V, et al.
Publicado: (2015)

Evaluation of B lymphocyte stimulator and a proliferation inducing ligand as candidate biomarkers in lupus nephritis based on clinical and histopathological outcome following induction therapy
por: Parodis, Ioannis, et al.
Publicado: (2015)

Pathogenic autoantibodies from patients with lupus nephritis cause reduced tyrosine phosphorylation of podocyte proteins, including tubulin
por: Manson, Jessica J, et al.
Publicado: (2014)

Value of repeat biopsy in lupus nephritis flares
por: Greloni, G, et al.
Publicado: (2014)

A multicentre, randomised controlled study of enteric-coated mycophenolate sodium for the treatment of relapsed or resistant proliferative lupus nephritis: an Asian experience
por: Anutrakulchai, Sirirat, et al.
Publicado: (2016)

Interferon (IFN)-λ is a potential mediator in lupus nephritis
por: Zickert, Agneta, et al.
Publicado: (2016)

Early proteinuria response: a valid real-life situation predictor of long-term lupus renal outcome in an ethnically diverse group with severe biopsy-proven nephritis?
por: Ugolini-Lopes, Michelle R, et al.
Publicado: (2017)

Causes and predictors of mortality in biopsy-proven lupus nephritis: the Sarawak experience
por: Teh, Cheng Lay, et al.
Publicado: (2018)

Serum albumin at 1 year predicts long-term renal outcome in lupus nephritis
por: Domingues, Vinicius, et al.
Publicado: (2018)

Outcome of participants with nephrotic syndrome in combined clinical trials of lupus nephritis
por: Gomez Mendez, Liliana Michelle, et al.
Publicado: (2019)

Development of a lupus nephritis suboptimal response prediction tool using renal histopathological and clinical laboratory variables at the time of diagnosis
por: Helget, Lindsay N, et al.
Publicado: (2021)

Membrane attack complex (MAC) deposition in renal tubules is associated with interstitial fibrosis and tubular atrophy: a pilot study
por: Wang, Shudan, et al.
Publicado: (2022)

Immune gene expression and functional networks in distinct lupus nephritis classes
por: Gilmore, Alyssa C, et al.
Publicado: (2022)

Discovery of NEU1 as a candidate renal biomarker for proliferative lupus nephritis chronicity
por: Mao, Zhaomin, et al.
Publicado: (2021)

Metformin improves renal injury of MRL/lpr lupus-prone mice via the AMPK/STAT3 pathway
por: Chen, Xiao-cui, et al.
Publicado: (2022)

Clinical and histological findings at second but not at first kidney biopsy predict end-stage kidney disease in a large multicentric cohort of patients with active lupus nephritis
por: Gatto, Mariele, et al.
Publicado: (2022)

Characteristics and renal survival of patients with lupus nephritis with glomerular immunoglobulin G(4) deposition: a single-centre retrospective analysis
por: Jiang, Xue, et al.
Publicado: (2022)

MOONLIGHT study: the design of a comparative study of the effectiveness of belimumab in patients with a history of lupus nephritis from the post-Marketed effectiveness of belimumab cOhOrt and JapaN Lupus NatIonwide reGistry (LUNA) coHorT
por: Sada, Kenei, et al.
Publicado: (2022)

Interleukin (IL) 16: a candidate urinary biomarker for proliferative lupus nephritis
por: Häyry, Aliisa, et al.
Publicado: (2022)

Urinary HER2, TWEAK and VCAM-1 levels are associated with new-onset proteinuria in paediatric lupus nephritis
por: Costa-Reis, Patricia, et al.
Publicado: (2022)

Predictors of increase in chronicity index and of kidney function impairment at repeat biopsy in lupus nephritis
por: Moroni, Gabriella, et al.
Publicado: (2022)

Response to therapy at 6 months predicts long-term renal outcome in lupus nephritis with poor kidney function
por: Luo, Huiting, et al.
Publicado: (2022)

Molecular signatures of intrarenal complement receptors C3AR1 and C5AR1 correlate with renal outcome in human lupus nephritis
por: Tampe, Désirée, et al.
Publicado: (2022)

Urinary markers differentially associate with kidney inflammatory activity and chronicity measures in patients with lupus nephritis
por: Akhgar, Ahmad, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ek856bn99nlo4sn1ri16rpiola